#Settlement

Astellas Pharma reached a settlement with Lupin and Zydus in the Myrbetriq® patent infringement lawsuit, receiving a total of USD 60 million in settlement payments and USD 150 million in upfront license fees.

The settlement of the U.S. litigation in which our subsidiary was a defendant was finally approved on February 2, 2026, and the impact on financial performance is expected to be minimal.

Regarding the shareholder derivative lawsuit, a settlement was reached whereby the defendants shall jointly pay 50 million yen to the joint litigants by March 31, 2026. The special profit is expected to be recorded in the fiscal year ending March 2026.